NCT03738865View on ClinicalTrials.gov

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

March 29, 2019

Study Completion Date

April 2, 2019

Conditions
Insulin HypoglycemiaType 1 Diabetes MellitusSevere Hypoglycemia
Interventions
DRUG

G-Pen

1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector

DRUG

Novo Glucagon

1 mg subcutaneous injection of Novo Glucagon (glucagon injection)

Trial Locations (7)

8010

Medizinische Universität Graz-Center for Medical Research, Graz

30318

Atlanta Diabetes Associates, Atlanta

89113

PPD-Las Vegas Clinical Research Unit, Las Vegas

94598

Diablo Clinical Research, Walnut Creek

98057

Rainier Research Center, Renton

M4G 3E8

LMC Diabetes & Endocrinology, Toronto

H3P 3P1

AltaSciences, Montreal

Sponsors
All Listed Sponsors
collaborator

Empiristat, Inc.

INDUSTRY

lead

Xeris Pharmaceuticals

INDUSTRY

NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes | Biotech Hunter | Biotech Hunter